isatuximab sold brand name sarclisa monoclonal antibody mab medication treatment multiple common side effects include neutropenia low levels neutrophils type white blood cell infusion reactions pneumonia infection lungs upper respiratory tract infection nose throat infections diarrhoea bronchitis inflammation airways isatuximab mab intended treat relapsed refractory multiple entered phase ii trials multiple tcell leukemia needs update united states indicated combination pomalidomide dexamethasone video ash treatment adults multiple myeloma received least two prior therapies including lenalidomide proteasome also indicated combination carfilzomib dexamethasone treatment adults relapsed refractory multiple myeloma received one three prior lines european union indicated combination pomalidomide dexamethasone treatment adults relapsed refractory multiple myeloma mm received least two prior therapies including lenalidomide proteasome inhibitor pi demonstrated disease progression last granted orphan drug designation multiple myeloma european medicines agency ema april us food drug administration fda december researchers started phase study isatuximab combination pomalidomide dexamethasone treatment patients multiple myeloma mm results phase trial showed patients discontinued treatment due progression disease patients already heavily pretreated latter lead manageable safety profile dose isatuximab combination pomalidomide dexamethasone would capped maximum mgkg weekly every two weeks future based remarkable findings phase trial phase ii trial launched researchers investigated isatuximab single agent patients mm heavily pretreated patients reacted well single administration isatuximab phase ii phase iii combination trial plasma cell myeloma comparing pomalidomide dexamethasone without isatuximab progress estimated completion date citation needed additionally two phase iii trials added first trial highlights whether added value combination isatuximab bortezomib lenalidomide dexamethasone latter tested patients newly diagnosed mm qualified transplant imroz trial second trial evaluates combinations isatuximab carfilzomib dexamethasone compared carfilzomib dexamethasone second trial designed patients previously treated one three prior lines ikema currentlywhen treatment mm however promising improvements made study still march approved medical use united us food drug administration fda approved isatuximabirfc march based evidence clinical trial subjects previously treated multiple trial conducted sites europe north america asia australia new trial evaluated efficacy side effects isatuximabirfc subjects previously treated multiple subjects randomly assigned receive either isatuximabirfc combination pomalidomide lowdose dexamethasone active comparator pomalidomide lowdose treatment administered groups cycles disease progression unacceptable subjects health care providers knew treatment trial measured time patients lived without cancer growing progressionfree survival approved medical use european union may structure isatuximab consists two identical immunoglobulin kappa light chains also two equal immunoglobulin gamma heavy chains chemically isatuximab similar structure reactivity daratumumab hence drugs show targeting however isatuximab shows potent inhibition ectozyme function latter gives potential noncross reactivity isatuximab shows action allosteric antagonist inhibition enzymatic activity additionally isatuximab shows potential induce apoptosis without cross lastly isatuximab reveals direct killing activity larger increase apoptosis detected expressing cancer cells furthermore isatuximab demonstrated dose dependent inhibition enzymatic activity however daratumumab experimental conditions shows limited inhibition without dose isatuximab binds uniquely epitope receptor antibody start apoptosis isatuximab binds different epitope aminoacid sequence monoclonal antibody binding receptor mainly via gamma heavy chains potent antibodies daratumumab inhibit enzymatic activity moreover isatuximab inhibits hydrolase activity citation needed antibodies show signs improving antitumor immunity eliminating regulatory cells b cells myeloidderived suppressor cells difference binding isatuximab daratumumab recognition different amino acid groups isatuximab identifies amino acids contrary daratumumab residue flexible sidechain faces nterminal residue isatuximab light chain latter light chain isatuximab also flexible makes interaction weaker interactions isatuximab caspasedependent apoptotic pathway lysosomal mediated cell death pathway mm cells induced isatuximab mm cell death follows downstream reactions lysosomal activation latter also activates production reactive oxygen isatuximab isatuximabirfc available drug intravenous infusion form injection doses ml mgml solution singledose vial ml mgml solution singledose cancer blood distinguished overproduction malignant plasma cells bone marrow called multiple myeloma myeloma cells marked uniformed overexpression surface glycoproteins although proteins also expressed myeloid lymphoid cells extent relatively minor compared myeloma cells fact glycoproteins carry various important cellular functions plentiful surface myeloma cells made appealing target multiple myeloma first described activation marker later molecule displayed functions adhesion endothelial proteins eg aiding component synapse complex well ectoenzyme implicated metabolism extracellular nad cytoplasmic nadp tumour cells evade immune system possibly due adenosine immunosuppressive molecule arises product ectoenzymatic activity isatuximabirfc monoclonal antibody selectively binds exists exterior hematopoietic multiple myeloma cells well tumor cells drug induces apoptosis tumor cells activates immune effector mechanisms complement dependent cytotoxicity cdc antibodydependent cellular phagocytosis adcp antibodydependent cellmediated cytotoxicity adcc isatuximabirfc able stimulate natural killer nk cells absence target tumor cells blocks tregulatory furthermore nadase activity adjusted isatuximab similarly antibodies contrarily daratumumab however isatuximab incite apoptosis directly without crosslinking binding according fda isatuximabirfc alone reduced adcc direct tumor cell killing activity vitro comparison combined pomalidomide well increased antitumor activity opposed isatuximabirfc pomalidomide human multiple myeloma xenograft isatuximabirfc likely metabolized catabolic pathways smaller peptides isatuximab constant state expected elimination occur approximately two months last dose administered clearance percentage diminished dosages increased time well multiple doses administered however elimination isatuximabirfc differ applied single agent combination doselimiting toxicity dlt characterized development following grade nonhematologic toxicity grade neutropenia grade thrombocytopenia lasting days grade allergic reactions hypersensitivity ie infusion reactions toxicity considered doselimiting investigators sponsor grade infusion reactions excluded dlt definition suitable care patients grade infusion reaction prior completion infusion able finalize isatuximab recommended reduced dose isatuximabirfc eventuality hematological toxicity may necessary delay administration blood count may although counteracting agent isatuximab clinical experience overdoses seemingly nonexistent well overdose symptoms probably line side effects attached isatuximab therefore infusion reactions gastrointestinal disturbances elevated risk infections may occur necessary carefully monitor patient case overdose employ clinically indicated symptomatic supportive studies conducted isatuximab concerning carcinogenicity genotoxicity given pregnant women isatuximabirfc cause fetal injury due mechanism action precipitate depletion immune cells well decreased bone density fetus pregnant women therefore notified potential risks fetus women able reproduce advised use effective contraceptives treatment least five months subsequent last dose isatuximabirfc furthermore recommended combine isatuximabirfc pomalidomide women carrying child pomalidomide may cause birth defects death unborn isatuximab indicated cytolytic antibody inhibiting enzymatic activity binding isatuximab multiple myeloma mm cells leads trigger several mechanisms leading direct apoptosis target cancer cells triggered pathways caspasedependent apoptotic lysosomemediated cell death pathway mm used combination dexamethasone pomalidomide drug thus treat patients multiple myeloma restrictions use isatuximab patients adults least received two previous treatments lenalidomide proteasome isatuximab currentlywhen also tested phase ii trial monotherapy refractoryrecurrent systemic lightchain phase iii study patients refractory relapsed mm resistant lenalidomide proteasome inhibitor could received daratumumab another monoclonal antibody published icariamm addition isatuximab pomalidomide dexamethasone improved progression free survival months compared months overall response rate adverse reactions isatuximabirfc may include neutropenia infusionrelated reactions andor secondary primary three commonly occurring ones infusionrelated examples frequent symptoms infusionrelated reactions dyspnea cough chills nausea severest signs symptoms included hypertension activity isatuximab researched mouse tumor models proven isatuximab leads antitumor activity mm cells furthermore combination isatuximab pomalidomide lead extra enhanced antitumor activity mm cells thus pomalidomide vivo vitro leads increase activity animal studies reproduction toxicity yet carried risks birth defects miscarriage risks isatuximab united states adopted name developed immunogen sanofiaventis development name needed httpsenwikipediaorgwikiisatuximab